ALLMedicine™ First-degree Atrioventricular Block Center
Research & Reviews 71 results
https://doi.org/10.1177/03331024221137092
Cephalalgia : an International Journal of Headache; Begasse de Dhaem O, Takizawa T et. al.
Feb 6th, 2023 - Long-term data helps assess the consistency of efficacy, tolerability, and safety of acute treatment over repeated use for different attacks. Real-world studies help assess tolerability, safety, and efficacy in patients with possibly refractory ch...
https://doi.org/10.1093/eurheartj/ehac799
European Heart Journal; Frimodt-Møller EK, Soliman EZ et. al.
Jan 21st, 2023 - Cardiac conduction disease can lead to syncope, heart failure, and death. The only available therapy is pacemaker implantation, with no established prevention strategies. Research to identify modifiable risk factors has been scant. Data from the C...
https://clinicaltrials.gov/ct2/show/NCT04645719
Nov 4th, 2022 - After approval by the Research Ethics Committee and registration of the project at ClinicalTrials (www.ClinicalTrials.gov) 75 patients will be selected from a population of obese patients scheduled for laparoscopic, bariatric or cholecystectomy su...
https://doi.org/10.1111/jocs.17093
Journal of Cardiac Surgery; Amirghofran AA, Nirooei E et. al.
Nov 3rd, 2022 - Several surgical techniques have been proposed to repair right partial anomalous pulmonary venous connection (PAPVC) along with sinus venosus defect (SVD). This study aimed to compare the perioperative data and outcomes of double-patch repair usin...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773717
ESC Heart Failure; Li S, Wang H et. al.
Sep 1st, 2022 - A 45-year-old male with cardiac sarcoidosis verified by cardiac biopsy presented with multiple coexisting arrhythmias, including ventricular tachycardia of more than 1000 episodes per 24 h, paroxysmal atrial fibrillation, and third-degree atrioven...
Drugs 19 results see all →
Clinicaltrials.gov 3 results
https://clinicaltrials.gov/ct2/show/NCT04645719
Nov 4th, 2022 - After approval by the Research Ethics Committee and registration of the project at ClinicalTrials (www.ClinicalTrials.gov) 75 patients will be selected from a population of obese patients scheduled for laparoscopic, bariatric or cholecystectomy su...
https://clinicaltrials.gov/ct2/show/NCT03973944
Aug 14th, 2019 - Rationale: Prolongation of the electrocardiographic PR interval (PR interval > 200ms; also known as first-degree atrioventricular block) is frequently encountered in clinical practice and is generally considered as a benign sign. However, there is...
https://clinicaltrials.gov/ct2/show/NCT03024047
Jan 18th, 2017 - Method: The following covariates will be reported. Date of diagnosis of AV-block: The date of diagnosis is defined as the day the physician diagnoses the AV-block. E.g. if the patient has a Holter monitoring performed, the date of diagnosis is the...
News 15 results
https://www.onclive.com/view/ibrutinib-rituximab-combo-represents-effective-chemo-free-option-for-elderly-patients-with-mcl
Jan 14th, 2022 - The combination of ibrutinib (Imbruvica) and rituximab (Rituxan) produced a high overall response rate (ORR) and durable survival in elderly patients with mantle cell lymphoma (MCL), according to data from a phase 2 ENRICH trial (NCT0180567) publi...
https://www.medpagetoday.com/neurology/alzheimersdisease/95523
Nov 8th, 2021 - A man treated with the recently approved Alzheimer's drug aducanumab (Aduhelm) had six amyloid-related imaging abnormality (ARIA) episodes, researchers reported. Over 44 months in a long-term extension study, the Alzheimer's disease patient had re...
https://www.medpagetoday.com/cardiology/pci/87583
Jul 15th, 2020 - Week-long continuous ECG monitoring was a worthwhile addition to the workup before transcatheter aortic valve replacement (TAVR), a small study suggested. Monitoring with the wearable CardioSTAT device over 7 days revealed arrhythmic events in 51 ...
https://www.mdedge.com/neurology/msresourcecenter/article/217365/multiple-sclerosis/relapsing-ms-ozanimod-tops-fingolimod?channel=251
Feb 14th, 2020 - Key clinical point: Ozanimod has a superior benefit-risk profile compared with fingolimod for the treatment of relapsing multiple sclerosis (RMS). Major finding: Compared with fingolimod, ozanimod was associated with lower rates of conduction abno.
https://www.mdedge.com/neurology/msresourcecenter/article/217365/multiple-sclerosis/relapsing-ms-ozanimod-tops-fingolimod
Feb 14th, 2020 - Key clinical point: Ozanimod has a superior benefit-risk profile compared with fingolimod for the treatment of relapsing multiple sclerosis (RMS). Major finding: Compared with fingolimod, ozanimod was associated with lower rates of conduction abno.